Back to results
US 9,789,115 B2Granted
Use of sigma ligands in opioid-induced hyperalgesia
AssigneeLaboratorios Del Dr. Esteve, S.A.
InventorsJosé Miguel Vela Hernández, Daniel Zamanillo-Castanedo, Margarita Puig Riera de Conias
Life of this patent
Estimating the term…
Abstract
The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat opioid-induced hyperalgesia (OIH) associated to opioid therapy.
Claims6
A method of treatment and/or prophylaxis of opioid-induced hyperalgesia (OIH) associated with opioid therapy in a patient, the method comprising:
- (a) providing a patient who is suffering from OIH associated with opioid therapy, undergoing opioid therapy, or about to undergo opioid therapy, wherein the patient who is undergoing opioid therapy or is about to undergo opioid therapy is or will be receiving a dose of opioid that would be expected to induce OIH in the patient;
- and
- (b) administering to the patient a therapeutically effective amount of a sigma ligand, wherein the sigma ligand is 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl} morpholine:
- or a pharmaceutically acceptable salt or solvate thereof,
- whereby OIH in the patient is treated, prevented, or ameliorated.
2 more elements
A method of treatment and/or prophylaxis of opioid-induced hyperalgesia (OIH) associated with opioid therapy in a patient, the method comprising:
- (a) providing a patient who is suffering from OIH associated with opioid therapy, undergoing opioid therapy, or about to undergo opioid therapy, wherein the patient who is undergoing opioid therapy or is about to undergo opioid therapy is or will be receiving a dose of opioid that would be expected to induce OIH in the patient;
- and
- (b) administering to the patient a therapeutically effective amount of a combination of at least one sigma ligand and at least one opioid or opiate compound, wherein said at least one sigma ligand and at least one opioid or compound are administered simultaneously, separately, or sequentially to the patient,
- wherein the sigma ligand is 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl} morpholine:
- or a pharmaceutically acceptable salt or solvate thereof,
- whereby OIH in the patient is treated, prevented, or ameliorated.
3 more elements
Dependencies are inferred from the claim text.